Updates of spinal muscular atrophy in advanced therapies
Open Access
- 18 October 2025
- journal article
- review article
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125, S73-S80
Abstract
No abstract availableKeywords
This publication has 89 references indexed in Scilit:
- Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudyMuscle & Nerve, 2023
- Biomarkers in 5q-associated spinal muscular atrophy—a narrative reviewJournal of Neurology, 2023
- Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseasesCellular and Molecular Life Sciences, 2022
- Scientific rationale for a higher dose of nusinersenAnnals of Clinical and Translational Neurology, 2022
- The 4‐Copy Conundrum in the Treatment of Infants with Spinal Muscular AtrophyAnnals of Neurology, 2022
- Reply to: The 4‐Copy Conundrum in the Treatment of Infants with Spinal Muscular AtrophyAnnals of Neurology, 2022
- Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular AtrophyJAMA Neurology, 2021
- Neurofilament as a potential biomarker for spinal muscular atrophyAnnals of Clinical and Translational Neurology, 2019
- Natural history of infantile‐onset spinal muscular atrophyAnnals of Neurology, 2017
- Natural history of denervation in SMA: Relation to age, SMN2 copy number, and functionAnnals of Neurology, 2005